Sciele Pharma, Inc., a Shionogi community, and Plethora Solutions Holdings PLC (”Plethora” AIMPLE), the specialist developer of produce for the treatment and management of urological disorders, today announced the final analysis of its European Phase III doubleblind placebocontrolled study of PSD502 for the treatment of premature ejaculation (PE). PSD502 has met not only its three coprimary endpoints of Intravaginal Ejaculation Latency space (IELT) and Index of Premature Ejaculation (IPE; Ejaculatory qualification and Sexual Satisfaction domains), but conjointly all secondary endpoints.

The outstanding European study is one of two pivotal Phase III studies conducted in parallel with identical protocols. The duplicate Phase III study is expected to be completed in the first half of 2009. measurements from the two studies will be combined for submission for regulatory approval in the USA and Europe.

Phase III Study Details

Each Phase III study is a multicenter, randomized, doubleblind, placebocontrolled efficacy study, and the program is expected to recruit a total of 540 patients crosswise the two studies. Patients are treated for a 12week period with an optional openlabel phase of up to nine months.

The European study was conducted with 300 randomized patients cross 32 investigational centers in four countries opposite Europe. Of these, 268 patients have now motheaten entered into the optional ninemonth openlabel study.

European Phase III Study Outcome

Final analyses confirmed not only that PSD502 produced a highly clinically and statistically significant cumulation from baseline in all three coprimary study endpoints, but furthermore in all secondary endpoints. The IELT for PSD502 was four minutes compared with one minute in placebo (p

Sciele Pharma, Inc., a Shionogi muster, and Plethora Solutions Holdings PLC (”Plethora” AIMPLE), the specialist developer of items for the treatment and management of urological disorders, today announced the final analysis of its European Phase III doubleblind placebocontrolled study of PSD502 for the treatment of premature ejaculation (PE). PSD502 has met not only its three coprimary endpoints of Intravaginal Ejaculation Latency day (IELT) and Index of Premature Ejaculation (IPE; Ejaculatory juice and Sexual Satisfaction domains), but more all secondary endpoints.

The champion European study is one of two pivotal Phase III studies conducted in parallel with identical protocols. The settle Phase III study is expected to be completed in the first half of 2009. measurements from the two studies will be combined for submission for regulatory approval in the USA and Europe.

Phase III Study Details

Each Phase III study is a multicenter, randomized, doubleblind, placebocontrolled efficacy study, and the program is expected to recruit a total of 540 patients crosswise the two studies. Patients are treated for a 12week period with an optional openlabel phase of up to nine months.

The European study was conducted with 300 randomized patients transversely 32 investigational centers in four countries crosswise Europe. Of these, 268 patients have now passй entered into the optional ninemonth openlabel study.

European Phase III Study Outcome

Final analyses confirmed not only that PSD502 produced a highly clinically and statistically significant incorporation from baseline in all three coprimary study endpoints, but still in all secondary endpoints. The IELT for PSD502 was four minutes compared with one minute in placebo (p

Sciele Pharma, Inc., a Shionogi assembly, and Plethora Solutions Holdings PLC (”Plethora” AIMPLE), the specialist developer of commodities for the treatment and management of urological disorders, today announced the final analysis of its European Phase III doubleblind placebocontrolled study of PSD502 for the treatment of premature ejaculation (PE). PSD502 has met not only its three coprimary endpoints of Intravaginal Ejaculation Latency bout (IELT) and Index of Premature Ejaculation (IPE; Ejaculatory drivers seat and Sexual Satisfaction domains), but as well all secondary endpoints.

The victorious European study is one of two pivotal Phase III studies conducted in parallel with identical protocols. The following Phase III study is expected to be completed in the first half of 2009. reports from the two studies will be combined for submission for regulatory approval in the USA and Europe.

Phase III Study Details

Each Phase III study is a multicenter, randomized, doubleblind, placebocontrolled efficacy study, and the program is expected to recruit a total of 540 patients transversely the two studies. Patients are treated for a 12week period with an optional openlabel phase of up to nine months.

The European study was conducted with 300 randomized patients crossed 32 investigational centers in four countries opposite Europe. Of these, 268 patients have now hasoldfangled entered into the optional ninemonth openlabel study.

European Phase III Study Outcome

Final analyses confirmed not only that PSD502 produced a highly clinically and statistically significant increment from baseline in all three coprimary study endpoints, but and in all secondary endpoints. The IELT for PSD502 was four minutes compared with one minute in placebo (p

UroToday.com When performing nerve sparing radical prostatectomy, how gigantic up on the lateral prostatic fascia do urologists hurting for to go to release the neurovascular bundle (NVB)? Are there even functional nerve fibers higher than the main bundle located at the 5 oclock position? that question is answered by Dr. Yasuhiro Kaiho and colleagues at Tohoku University in an on the internet report that recured in European Urology.

The investigators studied 12 potent men who underwent nerve sparing radical prostatectomy. Electrophysiological evaluation of functional periprostatic fascia was performed by stimulation to the periprostatic nerve network. The circumference of the prostate was labeled as 12 oclock at the anterior (top) position, 5 oclock at the NVB and 1, 2, 3, 4 in tween. These positions were stimulated at the midprostate for 30 anothers at 30mA in a monophasic pulse with pulse duration of 1.0ms. Response was measured as changes in urethral pressure at the middle portion of the penile shaft using an inserted balloon catheter to detect increases in cavernosal pressure. The amplitude responses for the 12 patients at each position on the prostate were averaged and compared to the other positions.

The amplitude was greatest when electrostimulation was applied at the 5 oclock position, followed by the 4 oclock position and decreased up to the 12 oclock position. that relatively straightforward materials suggests that the 5 and 4 oclock positions are the primary nerve sites, but additive benefit of additional sites was not evaluable.

Thus, mobilization of the lateral prostatic fascia as medially as imaginable will aid to protect the best nerves potential.

Kaiho Y, Nakagawa H, Saito H, Ito A, Ishidoya S, Saito S, Arai Y
Eur Urol. 2008 Sep 24. Epub ahead of print.
doi10.1016/j.eururo.2008.09.022

Written by UroToday.com Contributing Editor Christopher P. Evans, MD, FACS

UroToday the only urology website with original thought written by global urology key opinion leaders actively engaged in clinical practice.

To access the latest urology news releases from UroToday, go tourotoday.com

UroToday.com When performing nerve sparing radical prostatectomy, how alpine up on the lateral prostatic fascia do urologists be deficient to go to release the neurovascular bundle (NVB)? Are there even functional nerve fibers higher than the main bundle located at the 5 oclock position? that question is answered by Dr. Yasuhiro Kaiho and colleagues at Tohoku University in an on the internet report that rised in European Urology.

The investigators studied 12 potent men who underwent nerve sparing radical prostatectomy. Electrophysiological evaluation of functional periprostatic fascia was performed by stimulation to the periprostatic nerve network. The circumference of the prostate was labeled as 12 oclock at the anterior (top) position, 5 oclock at the NVB and 1, 2, 3, 4 in among. These positions were stimulated at the midprostate for 30 furthers at 30mA in a monophasic pulse with pulse duration of 1.0ms. Response was measured as changes in urethral pressure at the middle portion of the penile shaft using an inserted balloon catheter to detect increases in cavernosal pressure. The amplitude responses for the 12 patients at each position on the prostate were averaged and compared to the other positions.

The amplitude was greatest when electrostimulation was applied at the 5 oclock position, followed by the 4 oclock position and decreased up to the 12 oclock position. that relatively straightforward dossier suggests that the 5 and 4 oclock positions are the primary nerve sites, but additive benefit of additional sites was not evaluable.

Thus, mobilization of the lateral prostatic fascia as medially as attainable will advice to protect the better nerves mortal.

Kaiho Y, Nakagawa H, Saito H, Ito A, Ishidoya S, Saito S, Arai Y
Eur Urol. 2008 Sep 24. Epub ahead of print.
doi10.1016/j.eururo.2008.09.022

Written by UroToday.com Contributing Editor Christopher P. Evans, MD, FACS

UroToday the only urology website with original subject matter written by global urology key opinion leaders actively engaged in clinical practice.

To access the latest urology news releases from UroToday, go tourotoday.com